Mostrar el registro sencillo del ítem

dc.contributor.authorPardo-Moreno, Teresa
dc.contributor.authorGarcía Morales, Victoria 
dc.contributor.authorSuleiman-Martos, Sami
dc.contributor.authorRivas-Domínguez, Antonio
dc.contributor.authorMohamed-Mohamed, Himan
dc.contributor.authorRamos Rodríguez, Juan José
dc.contributor.authorMelguizo-Rodríguez, Lucía
dc.contributor.authorGonzález-Acedo, Anabel
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2024-05-30T10:35:02Z
dc.date.available2024-05-30T10:35:02Z
dc.date.issued2023
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10498/32443
dc.description.abstractParkinson’s disease (PD) is a neurodegenerative pathology, the origin of which is associated with the death of neuronal cells involved in the production of dopamine. The prevalence of PD has increased exponentially. The aim of this review was to describe the novel treatments for PD that are currently under investigation and study and the possible therapeutic targets. The pathophysiology of this disease is based on the formation of alpha-synuclein folds that generate Lewy bodies, which are cytotoxic and reduce dopamine levels. Most pharmacological treatments for PD target alphasynuclein to reduce the symptoms. These include treatments aimed at reducing the accumulation of alpha-synuclein (epigallocatechin), reducing its clearance via immunotherapy, inhibiting LRRK2, and upregulating cerebrosidase (ambroxol). Parkinson’s disease continues to be a pathology of unknown origin that generates a significant social cost for the patients who suffer from it. Although there is still no definitive cure for this disease at present, there are numerous treatments available aimed at reducing the symptomatology of PD in addition to other therapeutic alternatives that are still under investigation. However, the therapeutic approach to this pathology should include a combination of pharmacological and non-pharmacological strategies to maximise outcomes and improve symptomatological control in these patients. It is therefore necessary to delve deeper into the pathophysiology of the disease in order to improve these treatments and therefore the quality of life of the patients.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourcePharmaceutics - 2023, Vol. 15 n. 3 pp. 1-24es_ES
dc.subjectalpha-synucleines_ES
dc.subjectLewy bodieses_ES
dc.subjectParkinson’s diseasees_ES
dc.subjecttherapeutic targetses_ES
dc.titleCurrent Treatments and New, Tentative Therapies for Parkinson’s Diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/PHARMACEUTICS15030770
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI//PID2019-110960GB-I00es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//P18-RT-3324es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//P20-01293es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//P20-01061es_ES
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional